Cowen & Co. Assigns a Buy Rating on Syros Pharmaceuticals

By Jason Carr

In a report released today, Phil Nadeau from Cowen & Co. assigned a Buy rating to Syros Pharmaceuticals (NASDAQ: SYRS). The company’s shares opened today at $12.68.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.6% and a 57.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Syros Pharmaceuticals is a Moderate Buy with an average price target of $19.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.38 and a one-year low of $6.30. Currently, Syros Pharmaceuticals has an average volume of 200.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.